Bio-Pharm Archives - 17 중 2 번째 페이지

Celltrion Bets on Oral Obesity Drug: “The Wegovy Era Won’t Last Long”

Photo=Chairman Seo Jeongjin of Celltrion during the online press conference. Celltrion is set to enter the growing market for oral obesity drugs, aiming to overcome the limitations of existing therapies—such…

Park Pyeongtak

2025-11-19

Bukwang Pharm: “Spinning Off Danish Subsidiary and Strengthening Momentum for RNA Therapeutics Development”

Chairwoman Ahn Mi-jeong of Bukwang Pharm speaks during a corporate briefing on the 18th. photo=Park Pyeong tak Bukwang Pharm announced on the 18th that its Danish subsidiary Contera Pharma will…

Park Pyeongtak

2025-11-18

ABL Bio Sets Sights on Obesity Drug Market

ABL Bio, which recently secured a major technology licensing deal and equity investment from global pharma giant Eli Lilly, announced that its next strategic move will be entering the fast-growing…

Park Pyeongtak

2025-11-17

The Obesity Drug Boom: How Long Can the Rally Last?

A stock price soaring 6.1 times in just 10 months — from 49,100 won to 299,000 won — and a market capitalization jumping from 533 billion won (about USD 390…

Park Pyeongtak

2025-11-06

SK Biopharm’s Epilepsy Drug ‘Xcopri’ Wins Korean Approval

SK Biopharm’s Epilepsy Drug ‘Xcopri,’ with ₩400 Billion ($290 Million) Annual U.S. Sales, Wins Korean Approval SK Biopharm’s epilepsy medication Xcopri (generic name: cenobamate), which generates over ₩400 billion (approximately…

Cheon Okhyeon

2025-11-03

India’s Molbio Diagnostics Wins 18th Kochon Prize for TB Innovation

A round of applause filled a hall in Manila, the Philippines, on the evening of October 29, as an Indian company dedicated to fighting tuberculosis was named the winner of…

Cheon Okhyeon

2025-10-30

HK inno.N Nears KRW1 Trillion in Annual Sales

HK inno.N has recorded cumulative sales of around KRW770 billion($554 million) as of the third quarter this year, bringing the company closer than ever to achieving KRW1 trillion($720 million) in…

Park Pyeongtak

2025-10-29

Hanmi’s Obesity Drug Shows Up to 30% Weight Loss

Hanmi Pharmaceutical’s investigational obesity drug efeglenatide demonstrated weight loss of up to 30%, according to interim results from a Phase 3 clinical trial. The company announced on October 27 that…

Cheon Okhyeon

2025-10-27

HK inno.N Q3 Earnings to Shine on ‘K-CAB Effect’

Sales and operating profit projected to rise 19% and 32% year-on-year, respectivelyHK inno.N is expected to post strong results for the third quarter, driven by the robust domestic and overseas…

Cheon Okhyeon

2025-10-13

Alteogen Set to Accelerate Licensing After FDA Clears Keytruda SC

The U.S. Food and Drug Administration (FDA) has approved Merck’s (MSD) subcutaneous (SC) formulation of its blockbuster immunotherapy Keytruda, developed using Alteogen’s proprietary technology. Following the decision, analysts forecast not…

Cheon Okhyeon

2025-09-22